Metastatic Melanoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 49 expanded access programs, clinical trials, and compassionate use pathways listed for Metastatic Melanoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with metastatic melanoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 20 programs are currently active or recruiting, with the remaining 29 in other lifecycle stages. Sponsors actively running programs in this area include M.D. Anderson Cancer Center, Iovance Biotherapeutics, Inc., National Cancer Institute (NCI), Massachusetts General Hospital, NRG Oncology, and others.
By recruiting status
Snapshot of where every Metastatic Melanoma program currently sits in its lifecycle.
- Active / Recruiting20
- Inactive29
Top sponsors
Organisations running the most Metastatic Melanoma programs in the directory.
- M.D. Anderson Cancer Center7 programs
- Iovance Biotherapeutics, Inc.6 programs
- National Cancer Institute (NCI)6 programs
- Massachusetts General Hospital3 programs
- NRG Oncology2 programs
- Providence Health & Services2 programs
- Abramson Cancer Center at Penn Medicine1 program
- Anaveon AG1 program
- Brown University1 program
- California Pacific Medical Center Research Institute1 program
Metastatic Melanoma programs (49)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on ST101 for Patients with Advanced Solid Tumors — Sapience Therapeutics
- Study on Lifileucel (Tumor-infiltrating Lymphocytes) for Adults with Advanced Melanoma — Iovance Biotherapeutics, Inc.
- Study on the Safety and Effectiveness of IOV-3001 in Adults with Advanced Melanoma Receiving Lifileucel — Iovance Biotherapeutics, Inc.
- Study on Abbreviated MAPK Targeted Therapy Plus Pembrolizumab for Melanoma — Massachusetts General Hospital
- Study on Bevacizumab and Atezolizumab With or Without Cobimetinib for Treating Untreated Melanoma Brain Metastases — M.D. Anderson Cancer Center
- Study on Combining Two Immunotherapies (Cabozantinib and Nivolumab) for Treating Advanced Melanoma or Squamous Cell Head and Neck Cancer — National Cancer Institute (NCI)
- Study Comparing High-Dose IL-2 Alone and with Radiation Therapy for Metastatic Melanoma — Providence Health & Services
- Study on Using ctDNA to Guide Treatment with Ipilimumab, Nivolumab, and Relatlimab for Advanced Melanoma — NYU Langone Health
- Study on Gene-Modified T Cells With or Without Decitabine for Treating Advanced Cancers with NY-ESO-1 — Roswell Park Cancer Institute
- Study on Hepzato Kit and Opdualag for Treating Metastatic Melanoma with Liver Metastasis — University of Wisconsin, Madison
- Study on Ibrutinib for Treating Patients with Advanced Skin Melanoma That Hasn't Responded to Previous Treatments — National Cancer Institute (NCI)
- Study on IO102-IO103 and Pembrolizumab Combination vs. Pembrolizumab Alone for Advanced Melanoma — IO Biotech
- Study on Mirdametinib for Patients with Advanced NF1-Mutant Melanoma — Kevin Kim, MD
- Study on Morning Versus Afternoon Immunotherapy for Treating Advanced or Metastatic Solid Tumors — OHSU Knight Cancer Institute
- Study on Nivolumab with Trametinib and Dabrafenib, or Encorafenib and Binimetinib for Treating Advanced Melanoma with BRAF Mutation — M.D. Anderson Cancer Center
- Study on STC-15 and Toripalimab Combination Therapy for Advanced Cancers — STORM Therapeutics LTD
- Study on Stereotactic Radiosurgery for Patients with More Than 3 Melanoma Brain Metastases — M.D. Anderson Cancer Center
- Study Comparing Longer Radiation Therapy to Usual Radiation Therapy for Cancer Spread to the Brain — NRG Oncology
- Study on Adding Navitoclax to Dabrafenib and Trametinib for Treating BRAF Mutant Melanoma — National Cancer Institute (NCI)
- Study on Using Thermal Ablation and Precision Radiation for Treating Spine Cancer at Risk of Spinal Cord Compression — M.D. Anderson Cancer Center
- Study of ANV419 Alone or with Other Approved Treatments for Advanced Skin Melanoma (OMNIA-1) — Anaveon AG
- Study Comparing Encorafenib, Binimetinib, and Nivolumab with Ipilimumab and Nivolumab for Melanoma with Brain Metastases — SWOG Cancer Research Network
- A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer — Iovance Biotherapeutics, Inc.
- Study on Avapritinib for Treating CKIT or PDGFRA Mutation-Positive Advanced or Metastatic Solid Tumors — M.D. Anderson Cancer Center
- Study on Binimetinib and Encorafenib for Treating Metastatic Melanoma with Brain Metastases — M.D. Anderson Cancer Center
- Study on Cryoablation Combined with Ipilimumab and Nivolumab for Treating Melanoma — Massachusetts General Hospital
- Study on a New PD1-LAG3 Antibody for Patients with Advanced or Metastatic Solid Tumors — Hoffmann-La Roche
- Expanded Access Program for Lifileucel (LN-144) in Patients with Advanced Melanoma — Iovance Biotherapeutics, Inc.
- Study on GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo for Patients with Advanced Melanoma and Head and Neck Cancer — Providence Health & Services
- Immunotherapy with Prednisone and Sirolimus for Kidney Transplant Patients with Advanced Skin Cancer — National Cancer Institute (NCI)
- Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma — Abramson Cancer Center at Penn Medicine
- Study on Lifileucel with Reduced Dose Chemotherapy and Interleukin-2 for Treating Unremovable or Spread Melanoma — University of Kansas Medical Center
- Study on MC1R-targeted Alpha-particle Therapy and Combination with Nivolumab for Advanced Melanoma — Perspective Therapeutics
- Study on Natural Killer Cell Therapy and Temozolomide for Treating Stage IV Melanoma That Has Spread to the Brain — Kari Kendra
- Study on NovoTTF-200A Device and Pembrolizumab for Treating Melanoma Brain Metastasis — Brown University
- Study on PD-1 Antibody Therapy and Infliximab for Treating Metastatic Melanoma — Massachusetts General Hospital
- Study on Pembrolizumab and Lenvatinib for Patients with Brain Metastases from Melanoma or Kidney Cancer — Yale University
- Personalized Vaccine with Pembrolizumab for Treating Advanced Solid Tumors — Mayo Clinic
- Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma with HR Mutation — California Pacific Medical Center Research Institute
- Phase II Study of Pembrolizumab and Aldesleukin for Treating Advanced Melanoma and Kidney Cancer — National Cancer Institute (NCI)
- Study on Rigosertib and Pembrolizumab for Treating Unremovable or Spread Melanoma Resistant to PD-1 Inhibitors — Vanderbilt-Ingram Cancer Center
- Study on the Safety and Effectiveness of OBX-115 for Advanced Solid Tumors — Obsidian Therapeutics, Inc.
- Study on the Safety and Effects of ONC-392 Alone and with Anti-PD-1 in Advanced Solid Tumors and Non-Small Cell Lung Cancer — OncoC4, Inc.
- Study on Using a Patient's Own Immune Cells to Treat Solid Tumors — Iovance Biotherapeutics, Inc.
- Study of Oral Azacitidine and Pembrolizumab for Patients with Advanced Melanoma — M.D. Anderson Cancer Center
- Study on Lifileucel and Pembrolizumab Combination Compared to Pembrolizumab Alone for Untreated Advanced Melanoma — Iovance Biotherapeutics, Inc.
- Study on Adding Tazemetostat to Usual Treatment for Metastatic Melanoma That Has Progressed — National Cancer Institute (NCI)
- Study on Adding Whole Brain Radiotherapy with Memory Protection to Targeted Brain Radiation for Cancer Spread to the Brain — NRG Oncology
- Study on IL-2, Radiotherapy, and Pembrolizumab for Patients Not Responding to Checkpoint Blockade Therapy — Megan Daly, MD
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Metastatic Melanoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.